VIR - Earnings call transcript Q3 2024 | Vir Biotechnology, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Vir's third quarter 2024 financial results And business update call.

As a reminder, this conference call is being recorded. [Operator Instructions]

I will now turn the call over to Rich Lepke, Senior Director, Investor Relations.

You may begin, Mr. Lepke.

Richard Lepke

O'Byrne, afternoon. Chief today Eisner, Executive Medical and good De Dr. our and Officer. Officer; our Financial Backer, Officer; Jason you, With are me Marianne Chief Thank Chief our Dr. Mark

performance Before to from risks by uncertainties programs, our significantly we remind achievements the such some the Exchange are including forward-looking the the that and with of Securities implied or risks securities expressed or with today cause Commission, like future in Forms differ those laws. associated we reports clinical described making statements. and statements statements could business everyone and involve XX-K, filed and are substantial X-K. that company's statements forward-looking XX-Q I begin, These would are risks results, to under and development These our forward-looking uncertainties

to the turn now will call Backer. I CEO, over Marianne De our

Marianne De Backer

and agreement exclusive landmark with platform I'm progress an Sanofi's PRO-XTEN for Good Rich. oncology you joining masking thank you, this worldwide agreement diseases. clinical made engagers we've on today. us the infectious X use update beginning Sanofi. and quarter, afternoon, successful Thank with closing provide licensing proprietary to protease-cleavable masked This the everyone, of pleased for our and stage of T-cell includes significant

HERX, fight for This to VIR-XXXX believe enhancing We for higher aim PSMA T-cell allowing disease. dual-masked associated with of minimize mission our cell and typically to best-in-class thereby toxicity aligns the with engagers VIR-XXXX be therapies. These the and strategic EGFR to efficacy. investigational that treatments seamlessly move immune have for potential for the engagers, to dosing use system T power X VIR-XXXX the challenges

PRO-XTEN extensive from welcomed proven platform this be agreement, quickly to masking oncology scientific the technology. of and which bring part have key talented These have development expertise in and individuals leading our will synergies. with of engineering and As antibody employees we immunology, machine combined infrastructure capabilities within our believe learning that create organization. T-cell fit our excellent understanding deep robust and an We significant their Sanofi, expertise,

mid-stage our to on pipeline. clinical Moving

fully We are chronic like Much that recent ongoing opportunity represents progress a unmet strong important with next delta. health and trial upcoming promising with innovative significant integrated impactful a journey patients other patients. Hepatitis significant disease now value the our for the challenges the critical our commercial across programs market system. to highly opportunity and offer company. Phase severe outcomes becoming patients progress the delta for Vir, making This towards data II in and address care is therapies highlight health characterized hepatitis needs I'll markets, and readouts. orphan SOLSTICE an our point in HDV clinical for hepatitis by sustainable medical and inflection marking underscores in growth both substantial

patient hepatitis living We limited the and States in compliance are estimate treatment of therapies impact with treatment very U.S. available options. United long-term challenges approximately There self-administered Europe, often have requires there approximately subcutaneous and the presenting and the Europe. no Despite people and delta in are of in approved daily severe XXX,XXX patients XXX,XXX for currently injections, HDV, only life-threatening quality life. in

potential and of patients care to Phase transformative in option of standard shared has treatment current highly to data for regimen the have the a clinical elebsiran believe to our on date, we these be compared combination II Based we differentiated tobevibart and preliminary the need. is

testing the Feedback diagnosis HDV testing groups a B United involves infections hepatitis highlighted continue anticipate promising and States, early provider. advance hepatitis we a care treatment growing in This increase regions has advocacy treatment Reflex testing health rates. physicians we ensures for hepatitis positive for separate from test for who order interest in of and this an proactive to automatically As are like treatment, currently reflex both approach delta. the limited. patients in where without identification delta requiring even options from in

early, is ensure patients therapy identifying we By can help treatment once they timely approved. receive a

stages improve way at for awareness, early delta While towards we driving the pave of with outcomes approval. the to as HDV and aim program early diagnosis this effective patients potential for our a advances we closer are hepatitis treatment

are care testing stakeholders advocate key committed adopt We health to and these to the partnering across with practices. landscape for

Looking XX the the taking from Diego. SOLSTICE at AASLD will trial to place November present in ahead, data conference we San XX

excellent the in to are program HDV, engaged expected this and with advancing begin program have making is next in year. the which our to progress registrational We FDA planned clinic discuss

elebsiran B, like program functional of alpha. I'd interferon opportunity another and pegylated regulated regimen substantial tobevibart our our with to which cure or Next, hepatitis address for for without represents combination chronic

Our loss DNA United hepatitis after States a virus is alone and B detectable the in a a million this in goal an antigen of setting, defined functional million and patients There approximately treatment. globally. estimated of as X.X cure are $XXX surface B hepatitis hepatitis B sustained course finite

We to of trial reporting data at a Breaking Part AASLD the MARCH Late November. in are the B treatment looking presentation upcoming forward end from meeting in

cure XX% the excluding and This KOL data the is Based readout by XXXX. be quarter regimen second will functional XX% interferon-containing our for interferon. for for end-of-treatment on target in the regimen cure a feedback, of the data followed functional

commitment on provide Before I and like close, update informed progress. an reaffirm our our I keeping you events our to upcoming to would about

we had conduct we the on an November. focused an Day to event planned fourth hepatitis will franchise in While initially our instead in R&D quarter, investor in-depth host

reprioritization programs. we timing in at a results, to intend us XXXX. of the addition now ensuring progress our quarter initial dedicated provide T-cell adjusted to these of into our present We investor of plans. our prospects the clinical also engager Given T-cell programs, our to pipeline, event allows first discuss This of the we future engagers the have insights and and portfolio our subsequent

conference As November. exclusively focused hepatitis in following mentioned, we will host immediately the event an investor AASLD

delve for both X these programs MARCH we all critical keeping on strategy. are and the We allow understand approach updates with broader detailed the and deeply updated to SOLSTICE provide significant us into our focused on This development implications patients and will we our investors, developments. clear and importance of committed event, this and programs. communication clinical During the timely their to will you

Finally, of and have record as our President our excellence chapter in new Chief Executive Financial with welcomed organization. as month. O'Byrne more strategy a perfect public on for I'm Jason Officer Vice we companies. thrilled exceptional the focus operations execution, to financial His make an next years in leadership him this and fit and and a proven on track executive embark across accomplished is finance than Jason XX experience in earlier

here, has disciplined to priorities joining key of ensure stewardship. and one Jason's financial Since continued been capital deployment

stage clinical core opportunities recently operations. and are programs. and have focus we announced, our allowing initiative more to allocate us streamline we As These on a to prioritize strategic efforts restructuring efficiently our our implemented pipeline our resources

optimistic couldn't In Vir's the I potential impact therapies. more be innovative closing, about and our of future

We have a operations major strong us balance our points. fund allows sheet, to through inflection which next

We our focus shareholder value. most on expenses a with programs managing are our prudently promising and maximizing

for to provide dedicated programs Medical I'll hard Chief I and and team, would like now update support. and pipeline. for to thank our Eisner, with work continued investors to call clinical turn our that, including development their over our Officer; Mark new the Vice And an their Executive on our President colleagues our

Mark Eisner

good Thank and afternoon, you, everyone. Marianne,

trial the SOLSTICE with Let's hepatitis in delta. begin

the not Phase from achieved at preliminary In all we limit in in cohort virologic trial suppression we the X As Congress HDV of non-cirrhotic measurable presence lower reported participants, of a detected strong our RNA. reminder, and data target out EASL of SOLSTICE presented June. achieved of our no below quantification X II rollover X X indicating that HDV

achieved the of in cohort. the sustained rollover XX no combination suggesting antiviral normalization, cohort are virologic novo participants activity. There potential the novo participants At cohort the for cohort the in had durable the Additionally, were X was weeks participants and There XX X out observed of in de X cohort. in in of in de and combination monotherapy treatment. cohort, ALT XX combination monotherapy discontinuations analysis, XX combination suppression are the the the participants reached time

XX of adverse participants The XX achieved not site majority perspective, de regimens. a From or combination safety virologic ALT no and of were in events we normalization. flares a treatment-related detected. serious treatment, combination injection achieved mild achieved with the either also treatment adverse or transient of de of out incidence lower Seven all novo novo limit X in observed XX XX events After suppression reactions. of below X or ALT target the monotherapy quantification out grade X of weeks the cohort and low

data all promising Taken extremely and together, rapid are virologic these sustained demonstrated cohorts X preliminary responses. as

participants for XX AASLD. sharing be data beyond XX treatment treatment full for of well as approximately weeks We at available of the both as data will cohorts weeks of XX at participants set

also the Fast acceleration possible. to We U.S. to exploring combination tobevibart FDA for elebsiran. this from as are received a pleased bring quickly We're all patients pathways of actively therapy promising to investigational have as possible Designation Track and

information hepatitis conference. have of engaged these clinical hepatitis our discussions, forward registrational more the to Based investor following expedite at We our for to focused align with delta. working recently look strategy are on program. AASLD health development on sharing our we authorities to the actively event We initiation

participants of functional data include combination and B approximately followed and to post-treatment to the will II treatment combination This our our both end-of-treatment Phase trial, the triplet plus assess on by therapy the B. sharing Part data hepatitis our readout second we receiving from MARCH in XXXX, chronic XX to regimens. The which receiving participants evaluates will Moving XX data forward us AASLD, allow approximately regimens. for be At cure interferon. quarter for doublet will look program the which

discuss let's the Now and oncology programs. transition engager T-cell to

with briefly As second with clinically oncology. of provided on validated robust call, we Sanofi each of touch us the antigens agreement program. targeting in in I'll assets quarter portfolio described the our status a

highly T-cell with a address HERXxCDX dual-masked our in cancers. engager, it's needs HERX-expressing the significant to VIR-XXXX, potential unmet asset differentiated

development, we sites to first both particularly need a making HERX-positive masked significant sharing potentially anticipate with metastatic tumor The preliminary and indications. and As breast currently existing HERX-targeted is study study off-tumor the with pembrolizumab cancers, clinical data solid toxicity of progress are Phase VIR-XXXX and to T-cell a is active continued cancer Europe compared good therapies. the doses in higher efficacy basket The HERX lower quarter at for I and XX currently in as There in XXXX. monotherapy initially monotherapy dose offer is designed of colorectal conducted being in VIR-XXXX Australia, metastatic We improved escalation. ongoing, allowing only engager in cancer. unmet in evaluating a and in combination is

a need in of with patients trials. engager more represents significant a Phase many and VIR-XXXX PSMA in treatment burden dual-masked cancer currently directed effective I options. Prostate clinical T-cell is well-tolerated disease

designed is improved VIR-XXXX dual-masked PSMA toxicity to offer only doses to engager currently the in development, existing and As T-cell efficacy higher therapies. potentially for lower directed compared off-tumor clinical allowing PSMA-targeted

dose therapy. monotherapy The evaluating to first in a in potential the currently with anticipate fewer into to its study Phase is quarter I VIR-XXXX ongoing, early a compared sharing study of We The XXXX. as in for earlier with participants escalation is design VIR-XXXX progression expand step-up VIR-XXXX. the combination monotherapy data

Finally, option cancer and metastatic treatment potential we're for neck unmet these VIR-XXXX, IND, with to cancer. We target that settings head high. cell preparing for lung has cancers. patients study. in non-small the squamous second to provide the the metastatic initiate tumors The EGFR-expressing EGFRxCDX carcinoma, treatments, Despite believe VIR-XXXX and the colorectal line cleared metastatic initial dual-masked has patients types are difficult-to-treat a squamous remains a tumor and T-cell safe VIR-XXXX for clinical and cell beyond engager tolerable and a need for I available Phase

clinical on of first quarter study initiate track are Phase in to XXXX. in I enrollment We a the

With that, call to hand I'll now Jason. over the

Jason O’Byrne

to PRO-XTEN It's have to engager I assets executive continues disease Vir while And company's benefit its the I deliver of to shared, Thank to at the with underlying this patients impressive thank just meaningful long X Vir's treating the team you, addition important warm alongside talented employees masking Mark as look into history role and CFO, infectious create welcome. for Mark. and time disease Today, platform. the to value. an T-cell expanding Vir shareholder commitment the dedicated admired the and as and In successful join my the all focus execution. preventing you, working and also oncology to in proven Marianne team team's forward honor on infectious serious Vir the evolution. of

focus deliver position, positioned early my to are I deployment that of One mentioned, capital financial Marianne disciplined team, As our will confident with mission. Vir's stewardship. compelling programs be am well and strong areas clinical exceptional and we financial

quarter primarily third $XXX XXXX of compared partially were to by $XX.X and the Sanofi same the related now to $XXX million of results. decrease increase with was third highlights share associated approximately same the XXXX. cost-saving for discontinued will transaction offset I at of million The the to XXXX expense by $XXX approximately clinical XXXX quarter R&D the VIR-XXXX. quarter, of million period in XXXX. expenses quarter development to million largely the for related driven were costs SG&A the of end period $XX.X announced in manufacturing the was for for XXXX. expenses flu million initiatives reduced asset, The third compared this

our impairment by charges charges same long-lived Oregon for XXXX the period XXXX year. Restructuring last and August compared Portland, were charges primarily for to increase $XX.X the of related million the our million of asset severance closing quarter to related third restructuring was asset The driven facility. impairment and $X.X

cash, We at of investments the quarter ended with equivalents to quarter. $X.XX of $X.XX third the billion end approximately and compared cash the second billion

the in that the during approximately the quarter plus closing, to and XXXX, effects of is was included the amount quarter. investments $XX total of which $XX in to first-in-human million, million a and the the Excluding by the agreement, at reclassified third $XXX payments during Sanofi was the escrowed Sanofi to cash was $XX the decrease in The decrease escrowed achieving milestone $XXX in dosing million. effects and quarter million restricted cash subject approximately transaction, made million Sanofi cash cash VIR-XXXX payment. milestone investments Including

million million now guidance year, at our of full adjusting GAAP approach we the restructuring a $XXX expense lower and $XXX second million includes expense to our $XXX net $XXX is a updated guidance of million. Sanofi the stock-based of compared range items, Excluding are compensation part to $XXX year those XXXX of guidance the million, quarter we expenses, to latter transaction which range to X our million modestly to $XXX As

back the the that, call over to begin With Rich to turn I'll Q&A session.

Richard Lepke

concludes Jason. to over now it prepared Instructions] This you, turn you, Thank we operator. will and Q&A [Operator the section. remarks, our start I'll

Operator

Instructions] [Operator Choi to Goldman We'll at go Sachs. first Paul

Kyuwon Choi

Apologies end question of first us update the just mention of on is, your release. My missed press can FDA? if meeting in Phase with it status of II the you I planned the a

engager is looking comment on thinking So I for, the your second just of XXXX. your relative new what program you was status for the discussions the curious my for regulatory for Can you're question about the was? you're monotherapy both maybe pembrolizumab T-cell And measures how versus combination?

Marianne De Backer

give Thank questions. Mark, you to those very much for the question, to Paul. it I our answer CMO,

Mark Eisner

Yes. Thanks question, for the Paul.

as with have the mentioned. We engaged FDA you

at are the hepatitis on meeting further expect and development We about be on to that putting clinical to just we very share XX. program, touches our our investor November details able focused finishing

your XXXX In HERXxCDX is terms engager in of T-cell the particular, efficacy the in good program, question a one. program about

provide PSMA time, able program bit to a preliminary share at to data. be also planning X And perspective the on year. the next program, that are from We in monotherapy we'll data that quarter more

Operator

to Joseph Next, JPMorgan. will go at Eric

Eric Joseph

at just the terms your path comparator pivotal as randomized we based you a regulatory or combination expectation? sort the inclusion guess with be kind tobevibart? of that, or still of And how continued should within of -- thinking carry that of correctly, interaction, on a HDV, previously Hepcludex forward remember study in in should monotherapy latest outlined about I with I arm. I evaluation If we of guess

Mark Eisner

the Yes. Thanks for question.

to FDA. the everyone, Fast forward regimen. and and to as regimen for we with So stated Track the before, responses virologic committed combination And deep we of Designation going we've we combination the are because achieved elebsiran got tobevibart sustained remind for a with combination

more of plan on AASLD. the detail do terms our around this in discussing in event program, we details investor of further In

Operator

next Ulz to at Stanley. Morgan move Mike We'll

Michael Ulz

of ask trial the investor to any Or Maybe I be with just getting going this you're might at event? on Phase just the FDA. sort reveal and the things that at follow-up could just curious I'm your on point? III details final and a design you're are track feedback your interactions if unexpected

Mark Eisner

with will for a had you we very question. Thank the I the productive Yes. say FDA. meeting

and prepared with we at share on be closely the around think more I AASLD. to plan, them event investor the we'll very aligned details

Operator

Next, at to Barclays. Gena Wang we'll go

Huidong Wang

two have questions. I

the the very putting much one regarding first to the data The HDV prior is together Thank study. you from data.

should you week be patients XX, XX? -- points level assume with the lay minimum patient Should data and several for the But out those should now, focus achieve data that the the us Slide be not I normalization. patients, the So detectable should at more and rate here. ALT key XX we expect target benchmark level XX also are

you I remember, And deal saw regarding I Phase some the Marianne, said ongoing. T-cell my discussion Sanofi second engagers. you was is question when the data initial

So seen activity the hold more as year And data the patients, the initial monotherapy expectation? patient with update, your next now more the does data? have with you

Marianne De Backer

Okay. do data? comment very to Mark, on Gena. Thank you much, you want the HDV

Mark Eisner

absolutely. Yes,

SOLSTICE in a week So presentation the the we're and particularly through all study of at that. which give patients lot patients oral information, will beyond XX to AASLD made the study more think an meeting, I this going the HDV, have some of it

So to presenting going data. we're be those

delta In limit terms I not detected of quantification there's viral below getting undetectable means target the TND, absolutely. your yes, question levels. mean of around

that out there. So measurement the rigorous kind of most that's is

revealed XX% at EASL achieving what profound a in combination high very is very, in we the Our detected target reduction week not at rates viral regimen of load XX. above

plus that's normalization. data include a important TND included. normalization, ALT ALT be will those guidance FDA of and endpoint composite terms In of also The

coming AASLD we will So also that be will data the at up. present meeting

Marianne De Backer

the on engager, related remember with X. on agreement closed our to then question Sanofi And Gena, your that Yes. T-cell September

we be the on initial example, to I a available XXXX trial in And for on first sponsorship as position share programs. we all the So data both quarter will in we are and monotherapy on. of transitions, and of Obviously, data the XXXX the mentioned, the assets in the of have midst so XXXX.

Operator

Stranahan move of to at America. We'll Alec Bank next

Alec Stranahan

how was you to in maybe some And higher your the efficacy the as as for reach Or data could not Is ability we should driving things might safety dose? first MTD, if here? it this into for baked even frame or well? target for your XXXX dual-mask focusing dose escalation? expect we be I Will quarter. reach assets right Two hoping metrics initial and to well. is on speak about help the XXXX me way to and could a see you the sort maybe could to of the mostly be thinking benefit dosimetry

Mark Eisner

Sure.

quarter So in -- on terms from we are most T-cell will engager more this studies providing the we program not planning we're the both preliminary color providing VIR-XXXX, monotherapy next of your At year. as we I updates question, ongoing first data but in Phase HERX to program. X for VIR-XXXX really stated, of that, point, data PSA be and share we

And important. then your think, is I question about the dual-masking,

do our All dual-masking. of programs the have

T-cell antigen molecule. masking part the we're part binding the engager So the both molecule of tumor the CDX of and

So therapeutic better hypothesis the allow index. achieve that to is a will that, working here us

-- higher I higher safety safety. So mean, of with levels levels of efficacy good

As the in unmasked. the program before, but we PSMA PSMA. The program for clinical the program, dual-masked CDX we're development Janux masks part for the mentioned only HERX leaves

a in terms So differentiated may PSMA we think dual of our we of masking the asset molecule. have

Operator

go Partners. at Roanna Leerink Ruiz We'll to next

Nikola Gasic

to Roanna. enrich about III any on I target thinking follow-up could on trial HDV and those characteristics that. there you Are A on first baseline Phase And quick on be you Gasic are for here? population. design, the specific the guess, after HDV focusing for going cirrhotic This non-cirrhotics. Nik is Maybe patient

Mark Eisner

Sure.

question. for thanks So the

you'll both was If presented effect terms including anything, in both ALT the and non-cirrhotic SOLSTICE, in cirrhotic and data, patients very In cirrhotic fared when better. bit efficacy on that so back CPTAs in presented recall data, good these very, antiviral patients, little -- EASL, a we cirrhotics the and we non-cirrhotics.

the we both include our II on III So would program Phase so to base observations want clearly, non-cirrhotic from we cirrhotic the program patients. and Phase

on AASLD. kind characteristics, baseline provide to of enrichment, response our that we'll able terms predict any more think investor-focused of hepatitis that color around be at presentation I in In

tuned stay for there. more So detail

Nikola Gasic

then the read-through quarter the it. have looking And Got in second of helpful. what of data 'XX. sort HBV, cure functional That's data ahead, XX-week in end-of-treatment possible to could the

weeks, curious the Just you that in how HBs suppression what the rates, of into might see at XX could off-treatment sort heading mature antigen data XQ?

Mark Eisner

question. good really a that's No, Yes.

The of So doublet end-of-treatment we'll in have to as the the data, and triplet in liver and pegylated elebsiran summarize, with said, you next the QX addition interferon upcoming Diego. cure year. in functional meeting for data comes the just of tobevibart San

of before cure, functional is minimum looking in a So triplet in the we're functional we XX% cure XX% really, said the what doublet. for for

be XX to In of a there in of that is at is is going it's terms action, post based no establish that. drop-off and on end-of-treatment cure. prior clearly to least programs a not mechanisms clear that predicting there's weeks end-of-treatment of functional do But straightforward drop-off data, various between to treatment there markers

QX So we what soon. longer, taken next little end-of-treatment will have picture together, take and in for regimens And they patients. can cure summary, give I'd HBV what rate very will bit will is year. The data a complete the achieve of that just functional a say,

Operator

Nadeau We'll at Phil move next TD Cowen. to

Philip Nadeau

Two from us.

us final just disclose And the Analyst on be question, Meeting. time? then able the first, update broadly at suggested have the AASLD be time That's would meeting? HDV lines question. the design the you at to an program, And So the trial TCEs. the you've Will and pivotal able at to that second on you'll first give you design

simply you and potential those additional at studies? with or be this point Phase established You good mentioned differentiation HERX safe for Do enough to TCEs PMSA begin. the differentiation in future effective to move of spaces to see and either in I? Or in the need development other differentiation broadly in beyond is versus order to just

Mark Eisner

are we about to Phase final design. III information planning disclose design, trial question, the HDV the the more for So

able be you'll at So see around to that event investor AASLD. the

there. coming more that So

that lines. to on and when full we clarity we're additional lines, about time right look that, information do we now, time of will terms disclosing In have not

TCE Marianne, question, like In would the you me... terms of

Marianne De Backer

Sure.

Mark Eisner

Okay.

need PSMA. is So really data-driven to honest, to would what is a forward programs for we be be around your these and to see move going To HERX decision. question something that

I present very give monotherapy to at the in X, then preliminary think I start the we'll at course, of quarter look give of to -- a of like. looking that picture proof data we are stage, early what this look concept, programs we'll think

In we're the to terms I opine look that of to more yet, that your color future specific question, we think quite to on more at a ready answer provide but on will time point.

Operator

And Patrick we'll Trucchio H.C. Wainwright. go at to next

Patrick Trucchio

Just a couple of follow-up questions for me.

in maintain combination program, different more the the how confidence you be the on we've discuss First, data would clinical tobevibart including be in patients switch response normalization combination to doses at treatment and to level bulevirtide seen the regimen of based that virologic from to HDV can the would what expected and elebsiran of ALT bulevirtide higher from far. and so

be low to you cure program, Phase without then combination and all-comers? interferon. maybe about more if ahead S-antigen in S-antigen us with patients if if would XX% with to Or functional S-antigen And it pivotal at And the rate you this functional rates separately, rate baseline? in III would potential base Can on program low explore -- tell at combination about it stratifying look you're or in make sense a at talk us the thinking patients? we baseline baseline, can with the regarding XX% cure interferon anticipated tell these HBV is

Mark Eisner

Okay.

HDV. first on about So question your

tobevibart do XX% -- bulevirtide. The combination to improved get XX with was do elebsiran first expect about We data levels detected the the at of bulevirtide, EASL than versus that target based and higher much dose, on weeks. at of is not which part we our of we presented X-milligram

dose, isn't I dose isn't anywhere. -- Your about really that the approved higher question mean

-- what efficacy likely So expect thinking TND to the be see. bulevirtide level just have of superior to so we're to but I think about should even that we

or of terms a a level mean has such with and yes. to our continued be population in confidence in of enter In likely to on treatment from I virologic bulevirtide clinical much terms who bulevirtide. response practice, in expect of of higher combination been we who switch, the with terms trial is patient would our bulevirtide

is question, HBV your going think those just of meeting. stratified liver around the much all-comers versus tuned the for a March questions to terms on should become antigen. to at is guess baseline stay based I'd In the presentation question this I fundamentally, clearer be data ask at population your an surface I you and

Operator

And session you for this Thank back concludes the the Q&A and over Rich. call. I'll the turn of participating, to call

Richard Lepke

Thank for for in interest to in forward the Vir your appreciate and We and may call. our future. close this updates on today's further support you providing earnings the all you, continued Andre, your look concludes Thank progress call. you in participating our call.

Operator

does Thank you you. participation. call. that conference And your Thank conclude for today's

disconnect. now may You

Vir Biotechnology (VIR) 31 Oct 242024 Q3 Earnings call transcript